Streetbeat News

Stock Prices

BTCUSD

ETHUSD

SNXUSD

Bitcoin and Ethereum traded mostly flat, while Synthetix emerged as the top gainer over the past 24 hours. The global crypto market cap rose to $1.04 trillion, recording a 24-hour gain of 0.1%. Mantle was the biggest loser.

Portfolio Pulse from Lisa Levin

September 06, 2023 | 1:33 pm

TOST

UBS has upgraded Toast Inc. (TOST) from Neutral to Buy, leading to a rise in the company's stock.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2023 | 1:32 pm

JCSE

JE Cleantech Holdings Limited (NASDAQ:JCSE) has announced a stock repurchase program of up to $1,000,000 of the Company's outstanding Ordinary Shares. The program will commence immediately and the actual timing, number, and value of shares repurchased will be determined by management. The program may be suspended, terminated, or modified at any time.

Portfolio Pulse from Happy Mohamed

September 06, 2023 | 1:29 pm

ZS

Zscaler Inc's shares are trading slightly lower despite reporting a 43% YoY increase in Q4 revenue to $455.01 million, beating the consensus estimate of $430.42 million. The company also reported quarterly earnings of 64 cents per share, surpassing analyst estimates of 49 cents per share. For the fiscal first quarter, Zscaler anticipates revenue of $472 million to $474 million and earnings of 48 to 49 cents per share. Multiple analysts have reiterated or maintained their ratings, with price targets ranging from $175 to $210.

Portfolio Pulse from Adam Eckert

September 06, 2023 | 1:27 pm

BRGC

BRN

CVKD

MMLP

Insiders at four companies have recently made significant purchases of their own stocks. These include Barnwell Industries (BRN), Cadrenal Therapeutics (CVKD), BrightRock Gold (BRGC), and Martin Midstream Partners (MMLP). The purchases indicate the insiders' confidence in their companies' prospects.

Portfolio Pulse from Lisa Levin

September 06, 2023 | 1:25 pm

AKTS

Akoustis Technologies, Inc (NASDAQ:AKTS) reported Q4 FY23 revenue growth of 60.2% YoY to $8.33 million, missing the consensus of $8.44 million. The company also reported a gross loss of $1.7 million and a non-GAAP EPS loss of $0.21, both worse than expected. Despite this, the company remains optimistic about significant growth over the next two years. AKTS shares traded lower by 13.3% premarket.

Portfolio Pulse from Anusuya Lahiri

September 06, 2023 | 1:24 pm

AVAV

AeroVironment Inc's (NASDAQ:AVAV) shares are trading higher after reporting better-than-expected Q1 results and issuing strong guidance. The company reported revenues of $152.3 million, up 40% YoY, and earnings of $1 per share, beating estimates. The company also announced the acquisition of Tomahawk Robotics, expected to close in Q2. Following the results, Baird analyst Peter Arment upgraded AeroVironment from Neutral to Outperform and raised the price target from $95 to $128.

Portfolio Pulse from Adam Eckert

September 06, 2023 | 1:24 pm

META

X, formerly known as Twitter, has seen a 465% increase in video views in the last ten days, according to CEO Linda Yaccarino. This surge is attributed to changes in the video player interface and other improvements. The platform is also preparing to capitalize on the upcoming New York Fashion Week. Elon Musk, who has taken control of X, has been making efforts to transform it into an 'everything app', including enhancements to video consumption. Musk's initiatives are aimed at giving X an edge over Meta Platforms Inc.'s Facebook and Instagram.

Portfolio Pulse from Rounak Jain

September 06, 2023 | 1:24 pm

AMC

AMC Entertainment Holdings Inc (NYSE:AMC) shares are falling after the company entered into an equity distribution agreement to sell up to 40 million shares through an at-the-market offering. The company intends to use the net proceeds from the sale for various purposes including to bolster liquidity and repay existing debt. The news comes a week after AMC implemented a 10-to-1 reverse stock split.

Portfolio Pulse from Adam Eckert

September 06, 2023 | 1:23 pm

TRVN

Trevena Inc (NASDAQ:TRVN) released preliminary topline data from two Phase 1 proof-of-concept studies of TRV045, demonstrating CNS penetration and target engagement. The studies showed a statistically significant, dose-dependent reduction in mechanical allodynia. No serious adverse events were reported. Full safety and tolerability data is expected in early 4Q 2023. Concurrently, Trevena received a $15 million tranche under its non-dilutive ex-US royalty-based financing, triggered by the first commercial sale of Olinvyk in China. TRVN shares are up 23.4% at $1.08 during the premarket session.

Portfolio Pulse from Vandana Singh

September 06, 2023 | 1:23 pm